Anti-interleukin-6 autoantibodies in rheumatic diseases

Increased frequency in the sera of patients with systemic sclerosis

Hiroyuki Takemura, Hiroshi Suzuki, Kazuyuki Yoshizaki, Atsushi Ogata, Takamichi Yuhara, Takao Akama, Kazuhide Yamane, Heihachiro Kashiwagi

Research output: Contribution to journalArticle

50 Citations (Scopus)

Abstract

Objective. To investigate the presence and the roles of anti-interleukin-6 (anti-IL-6) autoantibodies in rheumatic diseases, and to further elucidate clinical and pathophysiologic significance of anticytokine autoantibodies. Methods. Anti-IL-6 IgG autoantibodies were measured by the 125I-IL-6 binding activity of IgG, which was isolated from serum by protein A-Sepharose. Results. Nine of 52 sera (17.3%) from patients with systemic sclerosis (SSc) contained anti-IL-6 antibodies, whereas only 1.9% of sera from normal subjects and 0-5% of sera from patients with other rheumatic diseases were positive for the antibodies. Moreover, anti-IL-6 autoantibodies were found predominantly among patients with the limited form of SSc (42.9%), compared with those with the diffuse form (7.9%). Conclusion. Anti-IL-6 IgG autoantibodies were detected in patients with SSc, particularly those with the limited form of the disease, at a significantly increased frequency compared with normal subjects and patients with other rheumatic diseases. These results suggest that the development of anti-IL-6 autoantibodies and IL-6 may have a role in the pathophysiology of SSc.

Original languageEnglish
Pages (from-to)940-943
Number of pages4
JournalArthritis and Rheumatism
Volume35
Issue number8
Publication statusPublished - 1992 Aug
Externally publishedYes

Fingerprint

Systemic Scleroderma
Rheumatic Diseases
Autoantibodies
Interleukin-6
Serum
Immunoglobulin G
Antibodies
Blood Proteins

ASJC Scopus subject areas

  • Immunology
  • Rheumatology

Cite this

Takemura, H., Suzuki, H., Yoshizaki, K., Ogata, A., Yuhara, T., Akama, T., ... Kashiwagi, H. (1992). Anti-interleukin-6 autoantibodies in rheumatic diseases: Increased frequency in the sera of patients with systemic sclerosis. Arthritis and Rheumatism, 35(8), 940-943.

Anti-interleukin-6 autoantibodies in rheumatic diseases : Increased frequency in the sera of patients with systemic sclerosis. / Takemura, Hiroyuki; Suzuki, Hiroshi; Yoshizaki, Kazuyuki; Ogata, Atsushi; Yuhara, Takamichi; Akama, Takao; Yamane, Kazuhide; Kashiwagi, Heihachiro.

In: Arthritis and Rheumatism, Vol. 35, No. 8, 08.1992, p. 940-943.

Research output: Contribution to journalArticle

Takemura, H, Suzuki, H, Yoshizaki, K, Ogata, A, Yuhara, T, Akama, T, Yamane, K & Kashiwagi, H 1992, 'Anti-interleukin-6 autoantibodies in rheumatic diseases: Increased frequency in the sera of patients with systemic sclerosis', Arthritis and Rheumatism, vol. 35, no. 8, pp. 940-943.
Takemura, Hiroyuki ; Suzuki, Hiroshi ; Yoshizaki, Kazuyuki ; Ogata, Atsushi ; Yuhara, Takamichi ; Akama, Takao ; Yamane, Kazuhide ; Kashiwagi, Heihachiro. / Anti-interleukin-6 autoantibodies in rheumatic diseases : Increased frequency in the sera of patients with systemic sclerosis. In: Arthritis and Rheumatism. 1992 ; Vol. 35, No. 8. pp. 940-943.
@article{dde01846a49e47b280c2c62d49f127e2,
title = "Anti-interleukin-6 autoantibodies in rheumatic diseases: Increased frequency in the sera of patients with systemic sclerosis",
abstract = "Objective. To investigate the presence and the roles of anti-interleukin-6 (anti-IL-6) autoantibodies in rheumatic diseases, and to further elucidate clinical and pathophysiologic significance of anticytokine autoantibodies. Methods. Anti-IL-6 IgG autoantibodies were measured by the 125I-IL-6 binding activity of IgG, which was isolated from serum by protein A-Sepharose. Results. Nine of 52 sera (17.3{\%}) from patients with systemic sclerosis (SSc) contained anti-IL-6 antibodies, whereas only 1.9{\%} of sera from normal subjects and 0-5{\%} of sera from patients with other rheumatic diseases were positive for the antibodies. Moreover, anti-IL-6 autoantibodies were found predominantly among patients with the limited form of SSc (42.9{\%}), compared with those with the diffuse form (7.9{\%}). Conclusion. Anti-IL-6 IgG autoantibodies were detected in patients with SSc, particularly those with the limited form of the disease, at a significantly increased frequency compared with normal subjects and patients with other rheumatic diseases. These results suggest that the development of anti-IL-6 autoantibodies and IL-6 may have a role in the pathophysiology of SSc.",
author = "Hiroyuki Takemura and Hiroshi Suzuki and Kazuyuki Yoshizaki and Atsushi Ogata and Takamichi Yuhara and Takao Akama and Kazuhide Yamane and Heihachiro Kashiwagi",
year = "1992",
month = "8",
language = "English",
volume = "35",
pages = "940--943",
journal = "Arthritis and Rheumatology",
issn = "2326-5191",
publisher = "John Wiley and Sons Ltd",
number = "8",

}

TY - JOUR

T1 - Anti-interleukin-6 autoantibodies in rheumatic diseases

T2 - Increased frequency in the sera of patients with systemic sclerosis

AU - Takemura, Hiroyuki

AU - Suzuki, Hiroshi

AU - Yoshizaki, Kazuyuki

AU - Ogata, Atsushi

AU - Yuhara, Takamichi

AU - Akama, Takao

AU - Yamane, Kazuhide

AU - Kashiwagi, Heihachiro

PY - 1992/8

Y1 - 1992/8

N2 - Objective. To investigate the presence and the roles of anti-interleukin-6 (anti-IL-6) autoantibodies in rheumatic diseases, and to further elucidate clinical and pathophysiologic significance of anticytokine autoantibodies. Methods. Anti-IL-6 IgG autoantibodies were measured by the 125I-IL-6 binding activity of IgG, which was isolated from serum by protein A-Sepharose. Results. Nine of 52 sera (17.3%) from patients with systemic sclerosis (SSc) contained anti-IL-6 antibodies, whereas only 1.9% of sera from normal subjects and 0-5% of sera from patients with other rheumatic diseases were positive for the antibodies. Moreover, anti-IL-6 autoantibodies were found predominantly among patients with the limited form of SSc (42.9%), compared with those with the diffuse form (7.9%). Conclusion. Anti-IL-6 IgG autoantibodies were detected in patients with SSc, particularly those with the limited form of the disease, at a significantly increased frequency compared with normal subjects and patients with other rheumatic diseases. These results suggest that the development of anti-IL-6 autoantibodies and IL-6 may have a role in the pathophysiology of SSc.

AB - Objective. To investigate the presence and the roles of anti-interleukin-6 (anti-IL-6) autoantibodies in rheumatic diseases, and to further elucidate clinical and pathophysiologic significance of anticytokine autoantibodies. Methods. Anti-IL-6 IgG autoantibodies were measured by the 125I-IL-6 binding activity of IgG, which was isolated from serum by protein A-Sepharose. Results. Nine of 52 sera (17.3%) from patients with systemic sclerosis (SSc) contained anti-IL-6 antibodies, whereas only 1.9% of sera from normal subjects and 0-5% of sera from patients with other rheumatic diseases were positive for the antibodies. Moreover, anti-IL-6 autoantibodies were found predominantly among patients with the limited form of SSc (42.9%), compared with those with the diffuse form (7.9%). Conclusion. Anti-IL-6 IgG autoantibodies were detected in patients with SSc, particularly those with the limited form of the disease, at a significantly increased frequency compared with normal subjects and patients with other rheumatic diseases. These results suggest that the development of anti-IL-6 autoantibodies and IL-6 may have a role in the pathophysiology of SSc.

UR - http://www.scopus.com/inward/record.url?scp=0026690770&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026690770&partnerID=8YFLogxK

M3 - Article

VL - 35

SP - 940

EP - 943

JO - Arthritis and Rheumatology

JF - Arthritis and Rheumatology

SN - 2326-5191

IS - 8

ER -